Assessing Repeatability of NeuroCatch Platform™ Measurements: An Initial Assessment

NCT03421405 | Completed

• 1 other identifier: NCI_NCClin_001
• Study Type: interventional
• Target: 10
• Locations: 1 country
• Sites: 1

Brief Summary

EEG signals have been collected and studied since the early 1990's as a way of assessing brain function at a gross level. As early as the 1930's a derivative of the raw EEG signal - event-related potentials (ERPs) - have been computed. These scalp-recorded ERPs are the brains response to a stimulus of interest (e.g. a flashing checkerboard or an angry face). The timing and topographical location of ERP components lends insight into the timing and complexity of various cognitive processes. At NeuroCatch Inc., research is primarily focused on three ERP components: the N100, P300 and N400. To elicit the ERP components of interest in this study (N100, P300, N400), proprietary auditory stimulus sequences will be administered using the investigational device, the NeuroCatch Platform™. Each sequence consists of pure tones and word pairs to elicit the various components associated with different attention abilities (sensory processing, target detection \& semantic processing). A secondary objective of the study will be to validate the auditory stimulus sequences tested. Understanding the degree to which these neurophysiological components fluctuate over time is crucial to our understanding of typical brain functioning. Research and medicine is moving away from behavioural responses to assess brain health (e.g. verbal responses, reaction time, etc.) and are moving toward more neuroimaging focused measures, such as CT, and MRI scans. The strength of utilizing EEG technology is two-fold: i) it is portable and ii) has high temporal resolution. Looking forward, EEG-based brain assessment technology could be implemented field-side, at the site of an accident for a quick assessment of brain and cognitive functioning, or within a clinicians' office to evaluate treatment efficacy. However, for this type of technology to be useful in quantifying brain health, we must first quantify the degree to which a healthy brain naturally fluctuates in it processing capability. For example, should technology such as the NeuroCatch Platform™ be used as a monitoring tool, we must have an idea of what normal variation is.

Conditions

Brain Health

Outcome Measures

Primary Outcomes (2)

• Variability of response size of selected ERPs (N100, P300, N400) acquired using the NeuroCatch Platform™ during the baseline visit

  Response size will be measured as amplitude in microvolts.

  1 day

• Variability of response timing of selected ERPs (N100, P300, N400) acquired using the NeuroCatch Platform™ during the baseline visit

  Response timing will be measured as latency in milliseconds.

  1 day

Secondary Outcomes (4)

• Qualitative comparison of ERP graphs generated by different auditory stimulus sequences during the NeuroCatch Platform™ assessment

  1 day

• Collection and evaluation of adverse events and adverse device effects

  4 weeks

• Slope of change over time in response size to quantify the natural variability in selected ERPs (N100, P300, N400) acquired using NeuroCatch Platform™

  4 weeks

• Slope of change over time in response timing to quantify the natural variability in selected ERPs (N100, P300, N400) acquired using NeuroCatch Platform™

  4 weeks

Study Arms (1)

Intervention Arm

EXPERIMENTAL

All participants will be asked to attend 4 separate experimental sessions over the course of approximately 4 weeks (i.e. one session/week). During each session, participants will listen to three different auditory stimulus sequences including sounds and words while EEG activity is recorded using the NeuroCatch Platform™ device.

Device: NeuroCatch Platform™

Interventions

NeuroCatch Platform™ DEVICE

NeuroCatch Platform™ consists of software and hardware that captures brain health information. The platform intends to provide a quick, portable and easy to use solution for the acquisition, display, analysis, storage, reporting and management of electroencephalograph (EEG) and event-related potential (ERP) information.

Intervention Arm

Eligibility Criteria

• Age: 19 Years - 65 Years
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Male or female, 19-65 years old inclusively
• Normal hearing capabilities
• Able to understand the informed consent form, study procedures and willing to participate in study
• Able to keep eyes still for min 6 minutes

You may not qualify if:

• Clinically documented hearing issues (e.g. tinnitus, in-ear hearing problems, punctured ear drum, etc.)
• Implanted pacemaker
• Metal or plastic implants in skull
• In-ear hearing aid or chocclear implant, hearing device
• Chronic neurological disorder (e.g. Stroke, MS, etc.)
• Recent (within last 6 months) acquired brain injury
• History of brain cancer
• History of dementia
• Exposed to investigational drug or device 30 days prior to start in this study, or concurrent use of investigational drug or device while enrolled in this study
• Planning to use investigational drugs or devices while enrolled in this study
• Not fluent in English language
• Unable to provide informed consent
• Previous participation in studies using the NeuroCatch Platform™
• If female and of child-bearing potential: pregnant, suspected or planning to become pregnant or breast-feeding
• History of seizures

Sponsors & Collaborators

• NeuroCatch Inc.: lead

Study Sites (1)

HealthTech Connex Inc. Centre for Neurology Studies

Vancouver, British Columbia, V3V 0C6, Canada

Location

Study Officials

• Jan Venter, MBChB MFamMed CCFP IFMCP

  HealthTech Connex Inc. Centre for Neurology Studies

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: NA
• Masking: NONE
• Purpose: DEVICE FEASIBILITY
• Intervention Model: SINGLE GROUP
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Model Details: All participants will be asked to attend 4 separate experimental sessions over the course of approximately 4 weeks (i.e. one session/week). During each session, participants will listen to three different auditory stimulus sequences including sounds and words while EEG activity is recorded. There will be 5-minute break between each audio sequence. Each experimental session will take approximately 30-45 minutes to complete.

Study Record Dates

• First Submitted: January 23, 2018
• First Posted: February 5, 2018
• Study Start: January 2, 2018
• Primary Completion: February 1, 2018
• Study Completion: February 1, 2018
• Last Updated: March 18, 2021

Record last verified: 2021-03

Locations

CA (1)